Muscle Relaxant Drugs Market Size & Share, by Therapeutic Group (Neuromuscular Blockers, Spasmolytic); Formulation (Cyclobenzaprine, Carisoprodol, Chlorzoxazone); Route of Administration (Oral, Injectable); End-user (Hospital Pharmacy, Retail Pharmacy) - Global Supply & Demand Analysis, Growth Forecasts, Statistics Report 2023-2033

  • Report ID: 486
  • Published Date: Feb 13, 2023
  • Report Format: PDF, PPT

Companies Dominating the Muscle Relaxant Drugs Landscape

top-features-companies
    • AbbVie Inc.
      • Company Overview
      • Business Strategy
      • Key Product Offerings
      • Financial Performance
      • Key Performance Indicators
      • Risk Analysis
      • Recent Development
      • Regional Presence
      • SWOT Analysis
    • Antisense Therapeutics Limited
    • Sandoz International GmbH
    • Abbott Laboratories
    • Pfizer, Inc.
    • Merck & Co., Inc.
    • SteriMax Inc.
    • Vertical Pharmaceuticals, LLC
    • Instas Pharmaceuticals Ltd.
    • F. Hoffmann-La Roche Ltd.

Browse Key Market Insights with Data Illustration:

In-the-news

In The News

  • AbbVie Inc., announced the approval of upadacitinib (RINVOQ) for the treatment of active non-radiographic axial spondyloarthritis in patients with signs of inflammation who have responded inadequately to nonsteroidal anti-inflammatory drugs (NSAIDs).

  • Antisense Therapeutics Limited- announced a scientific exploration into a new muscle disease indication for ATL1102 – Limb Girdle Muscular Dystrophy R2.


Author Credits:  Radhika Gupta, Shivam Bhutani


  • Report ID: 486
  • Published Date: Feb 13, 2023
  • Report Format: PDF, PPT

Frequently Asked Questions (FAQ)

Upsurge in the use of muscle relaxants with other anaesthetics during surgical procedures, increasing sedentary lifestyle and decreasing levels of activity are the major factors driving the growth of the market.

The market is anticipated to attain a CAGR of 7% over the forecast period, i.e., 2023-2033.

Side effects associated with other drugs, liver damage, respiratory disorder and use of muscle relaxant drugs as temporary relief provider are estimated to hamper the market growth.

The market in North America is projected to hold the largest market share by the end of 2033 and provide more business opportunities in the future.

The major players in the market are AbbVie Inc., Sandoz International GmbH, Abbott Laboratories, Pfizer, Inc., Merck & Co., Inc., SteriMax Inc., Vertical Pharmaceuticals, LLC, Instas Pharmaceuticals Ltd. and others.

The company profiles are selected based on the revenues generated from the product segment, geographical presence of the company which determine the revenue generating capacity as well as the new products being launched into the market by the company.

The market is segmented by therapeutic group, formulation, route of administration, end user and by region.

The neuromuscular blocker is anticipated to garner the largest market size by the end of 2033 and display significant growth opportunities.
Inquiry Before Buying Request Free Sample
  GET A FREE SAMPLE

FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.

 Request Free Sample Copy

Have questions before ordering this report?

Inquiry Before Buying